scholarly journals Impact of adjuvant chemotherapy in patients with adverse features and variant histology at radical cystectomy for muscle‐invasive carcinoma of the bladder: Does histologic subtype matter?

Cancer ◽  
2019 ◽  
Vol 125 (9) ◽  
pp. 1449-1458 ◽  
Author(s):  
Sebastian Berg ◽  
David D’Andrea ◽  
Malte W. Vetterlein ◽  
Alexander P. Cole ◽  
Sean A. Fletcher ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Carcinoma ◽  
Histologic Subtype ◽  
Variant Histology ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

scholarly journals Orthotopic urinary diversion after radical cystectomy in treatment of muscle invasive bladder cancer

2014 ◽  
Vol 61 (1) ◽  
pp. 63-67
Author(s):  
Jovan Hadzi-Djokic ◽  
Vladan Andrejevic ◽  
Tomislav Pejcic ◽  
Miodrag Acimovic ◽  
Uros Babic ◽  
...  
Keyword(s):  
Radical Cystectomy ◽  
Urinary Diversion ◽  
Invasive Carcinoma ◽  
Complete Removal ◽  
Continent Urinary Diversion ◽  
Muscle Invasive Bladder Cancer ◽  
Orthotopic Urinary Diversion ◽  
Carcinoma Of The Bladder ◽  
Muscle Invasive

Surgical treatment of invasive carcinoma of the bladder in males includes total cystectomy remo?al of the prostate, seminal vesicles, and the distal parts of the urethers and the pelvic lymph node dissection as well. At this moment it is not possible to recommend a particular type of urinary diversion, but today in clinical practice commonly used derivative are ileal orthotopic neobladder as the continent one and ileal conduit as non-continent urinary diversion. Continent urinary diversion after radical cystectomy are the result of the application of technological innovation in surgery, but also knowledge, imagination and skill of well trained urologist. This type of operation significantly improves the quality of life in patients who underwent radical cystectomy, and the proposal is to operate when- ever there is a possibility for this type of procedure. Also it is very important, during surgery to respect oncological principles, of complete removal of tumorous tissue and that the functional principle of ensuring that the patients have daytime and also nighttime continence later on after the surgery.

Role of adjuvant chemotherapy in the treatment of invasive carcinoma of the urinary bladder.

1998 ◽  
Vol 16 (4) ◽  
pp. 1601-1612 ◽  
Author(s):  
M A Dimopoulos ◽  
L A Moulopoulos
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Invasive Carcinoma ◽  
Disease Free Survival ◽  
Muscle Invasive Bladder Cancer ◽  
Free Survival ◽  
Muscle Invasive ◽  
Disease Free

PURPOSE The standard treatment for patients with muscle-invasive carcinoma of the urinary bladder is radical cystectomy. While radical cystectomy cures many patients with this tumor, almost 50% of them will develop metastatic disease. Adjuvant chemotherapy has been proposed for these patients in an attempt to reduce the probability of relapse and to improve survival. To assess whether adjuvant chemotherapy does benefit patients with muscle-invasive bladder cancer, we reviewed all phase II and III studies published in the English literature over the last 20 years. METHODS A review of all published reports was facilitated by the use of Medline computer search and by manual search of the Index Medicus. RESULTS Several comparative, nonrandomized studies have indicated that adjuvant chemotherapy may prolong disease-free survival. Four randomized studies have been conducted and all had a suboptimal patient accrual. Three studies used a cisplatin-containing combination chemotherapy and included primarily patients with non-organ-confined transitional-cell carcinoma (TCC) of the bladder. All three studies indicated that adjuvant chemotherapy improved disease-free survival and two of them also showed improvement in event-free survival and overall survival, respectively. CONCLUSION Published series have been unable to establish an undisputed benefit of adjuvant chemotherapy over radical cystectomy alone for muscle-invasive bladder cancer. The interpretation of the available data is compromised by several methodologic and statistical problems. Thus, adjuvant chemotherapy cannot be considered as a standard treatment for all patients with muscle-invasive carcinoma of the bladder. Well-designed prospective randomized studies are needed to clarify the role of adjuvant chemotherapy in this disease. However, outside a protocol setting, there is some evidence that patients with extravesical disease or with lymph node involvement may benefit from adjuvant treatment with cisplatin-based combination chemotherapy. No data support such an approach for patients with muscle-invasive but organ-confined bladder cancer.

scholarly journals Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy

2020 ◽  
Vol 19 ◽  
pp. e1586-e1587
Author(s):  
S. Zamboni ◽  
P. Baumeister ◽  
A. Aziz ◽  
C. Poyet ◽  
C. Simeone ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Variant Histology
Sign in / Sign up

Export Citation Format

Share Document